Life sciences continues its attractive run as an asset class for commercial real estate investors in the US and now Canada is stepping forward to develop its own opportunities.
Sabrina Solomiany, Senior Managing Director, Head of Medical & Life Sciences, Berkadia, led a discussion with Maureen McCaffrey, PE, LEED, AP, Director MIT Investment Management Company, and Milos Dajic, CFA, Vice President, Investments, Oxford Properties Group, at last week's CREW Network conference in Atlanta.
"Covid was a wakeup call for Canada, teaching it that it needs to create labs for vaccine development, so it doesn't have to rely on the US and elsewhere," Dajic said. The key Canadian target markets are Toronto, Montreal, and Vancouver.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
